CA3212314A1 - Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma - Google Patents

Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma Download PDF

Info

Publication number
CA3212314A1
CA3212314A1 CA3212314A CA3212314A CA3212314A1 CA 3212314 A1 CA3212314 A1 CA 3212314A1 CA 3212314 A CA3212314 A CA 3212314A CA 3212314 A CA3212314 A CA 3212314A CA 3212314 A1 CA3212314 A1 CA 3212314A1
Authority
CA
Canada
Prior art keywords
oxadiazin
dihydro
group
trifluoromethyl
pheny1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3212314A
Other languages
English (en)
French (fr)
Inventor
Martin Lange
Stefan KAULFUSS
Charlotte Christine Kopitz
Heidi GREULICH
Xiaoyun Wu
Matthew Meyerson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Dana Farber Cancer Institute Inc
Broad Institute
Original Assignee
Bayer AG
Dana Farber Cancer Institute Inc
Broad Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Dana Farber Cancer Institute Inc, Broad Institute filed Critical Bayer AG
Publication of CA3212314A1 publication Critical patent/CA3212314A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3212314A 2021-03-03 2022-03-02 Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma Pending CA3212314A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156193P 2021-03-03 2021-03-03
US63/156,193 2021-03-03
PCT/EP2022/055211 WO2022184748A1 (en) 2021-03-03 2022-03-02 Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma

Publications (1)

Publication Number Publication Date
CA3212314A1 true CA3212314A1 (en) 2022-09-09

Family

ID=80780814

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3212314A Pending CA3212314A1 (en) 2021-03-03 2022-03-02 Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma

Country Status (7)

Country Link
US (1) US20230405015A1 (enExample)
EP (1) EP4301371A1 (enExample)
JP (1) JP2024508171A (enExample)
CN (1) CN117279644A (enExample)
CA (1) CA3212314A1 (enExample)
TW (1) TW202302113A (enExample)
WO (1) WO2022184748A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120187704A (zh) * 2022-11-24 2025-06-20 盛睿泽华医药科技（苏州）有限公司 吡啶酮化合物及其制备方法和用途
CN118420559B (zh) * 2023-04-27 2025-02-14 上海超阳药业有限公司 氘代噁二嗪酮化合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150361A (en) * 1998-12-22 2000-11-21 Bayer Corporation Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma
JP6445573B2 (ja) * 2013-10-17 2018-12-26 サルタル セラピューティクス エルティーディＳａｒｔａｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ ヒト患者の固形腫瘍の治療に用いるためのホスホジエステラーゼ阻害剤含有組成物
CN106573931A (zh) * 2014-06-18 2017-04-19 拜耳医药股份有限公司 抑制BET蛋白的具有间位取代的芳族氨基或醚基的3，4‑二氢吡啶并[2，3‑b]吡嗪酮
WO2017027854A1 (en) * 2015-08-13 2017-02-16 The Broad Institute, Inc. Compositions and methods for cancer expressing pde3a or slfn12
TW201733591A (zh) * 2016-02-05 2017-10-01 拜耳製藥公司 用於癌症病人分級及癌症治療之化合物、組合物及方法
US11142522B2 (en) * 2017-02-03 2021-10-12 The Broad Institute, Inc. Compounds, compositions and methods for cancer treatment
JOP20200024A1 (ar) * 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون

Also Published As

Publication number Publication date
EP4301371A1 (en) 2024-01-10
JP2024508171A (ja) 2024-02-22
TW202302113A (zh) 2023-01-16
WO2022184748A1 (en) 2022-09-09
CN117279644A (zh) 2023-12-22
US20230405015A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
US12486248B2 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH
US11964953B2 (en) Substituted aminothiazoles as DGKzeta inhibitors for immune activation
US11787797B2 (en) 4,5-annulated 1,2,4-triazolones
US20230064809A1 (en) Substituted aminoquinolones as dgkalpha inhibitors for immune activation
EP4602049A1 (en) Sos1 inhibitors
US20230357239A1 (en) Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors
US10179123B2 (en) 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors
US20230017200A1 (en) Dihydrooxadiazinones
AU2022258751A1 (en) Phosphorus derivatives as novel sos1 inhibitors
US11660301B2 (en) Combination of ATR kinase inhibitors with PARP inhibitors
US20230405015A1 (en) Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma
US20210369724A1 (en) Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
WO2024165470A1 (en) Combinations of dgk (diacylglycerol kinase) inhibitors
US20170217946A1 (en) Amino-substituted isoxazoles
WO2018215282A1 (en) Combination of bub1 and pi3k inhibitors
HK40105245A (en) Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma
CA3270230A1 (en) Crystalline forms of her2/mutegfr inhibitors and process for their preparation
WO2016202759A1 (en) Cytotoxic substituted 2-(1 h-pyrazol-1 -yl)-1,3-benzothiazole compounds for the treatment of cancer

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250218

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250225

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250528

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250724

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260423

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260526